Phio Pharmaceuticals (PHIO) Competitors $2.33 -0.05 (-2.10%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.32 -0.01 (-0.60%) As of 08/1/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHIO vs. PRLD, KALA, CGTX, NRXP, KLRS, ABVC, GANX, OSTX, SNTI, and VTVTShould you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Prelude Therapeutics (PRLD), KALA BIO (KALA), Cognition Therapeutics (CGTX), NRx Pharmaceuticals (NRXP), Kalaris Therapeutics (KLRS), ABVC BioPharma (ABVC), Gain Therapeutics (GANX), OS Therapies (OSTX), Senti Biosciences (SNTI), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry. Phio Pharmaceuticals vs. Its Competitors Prelude Therapeutics KALA BIO Cognition Therapeutics NRx Pharmaceuticals Kalaris Therapeutics ABVC BioPharma Gain Therapeutics OS Therapies Senti Biosciences vTv Therapeutics Prelude Therapeutics (NASDAQ:PRLD) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings. Does the media favor PRLD or PHIO? In the previous week, Prelude Therapeutics' average media sentiment score of 0.00 equaled Phio Pharmaceuticals'average media sentiment score. Company Overall Sentiment Prelude Therapeutics Neutral Phio Pharmaceuticals Neutral Do analysts rate PRLD or PHIO? Prelude Therapeutics currently has a consensus target price of $4.50, suggesting a potential upside of 443.28%. Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 500.86%. Given Phio Pharmaceuticals' higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Prelude Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prelude Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Phio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is PRLD or PHIO more profitable? Prelude Therapeutics' return on equity of -89.18% beat Phio Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Prelude TherapeuticsN/A -89.18% -69.26% Phio Pharmaceuticals N/A -105.65%-89.19% Do insiders & institutionals have more ownership in PRLD or PHIO? 79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 63.9% of Prelude Therapeutics shares are held by company insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more risk & volatility, PRLD or PHIO? Prelude Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Which has higher earnings & valuation, PRLD or PHIO? Phio Pharmaceuticals has lower revenue, but higher earnings than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrelude Therapeutics$7M6.68-$127.17M-$1.69-0.49Phio PharmaceuticalsN/AN/A-$7.15M-$6.42-0.36 SummaryPrelude Therapeutics beats Phio Pharmaceuticals on 8 of the 11 factors compared between the two stocks. Get Phio Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHIO vs. The Competition Export to ExcelMetricPhio PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.18M$2.50B$5.52B$9.37BDividend YieldN/A1.80%4.74%4.13%P/E Ratio-0.369.0928.9923.78Price / SalesN/A687.56440.1095.97Price / CashN/A155.1435.0756.59Price / Book3.384.838.255.54Net Income-$7.15M$31.62M$3.25B$259.97M7 Day Performance-14.96%-5.28%-3.75%-4.67%1 Month Performance-4.27%3.12%2.99%3.29%1 Year Performance-20.29%-2.00%25.34%17.92% Phio Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHIOPhio Pharmaceuticals2.5472 of 5 stars$2.33-2.1%$14.00+500.9%-20.2%$11.18MN/A-0.3610PRLDPrelude Therapeutics3.2586 of 5 stars$0.85-8.4%$4.50+428.1%-85.8%$52.51M$7M-0.50120High Trading VolumeKALAKALA BIO3.5041 of 5 stars$7.93-2.0%$13.00+63.9%+27.1%$52.20M$3.89M-0.9630Upcoming EarningsCGTXCognition Therapeutics2.3983 of 5 stars$0.72-14.9%$2.83+296.2%-8.4%$52.07MN/A-0.9720Upcoming EarningsShort Interest ↑Gap DownNRXPNRx Pharmaceuticals2.7679 of 5 stars$2.93-2.3%$28.50+872.7%+22.2%$51.87MN/A-1.462KLRSKalaris TherapeuticsN/A$2.92+5.8%$3.00+2.7%N/A$51.62MN/A0.00110Positive NewsABVCABVC BioPharma0.511 of 5 stars$3.02+0.3%N/A+281.9%$51.12M$510K-23.2330GANXGain Therapeutics2.3057 of 5 stars$1.62-4.1%$8.20+406.2%+37.1%$50.82M$50K-1.8820Upcoming EarningsOSTXOS Therapies2.1005 of 5 stars$1.80flat$18.00+900.0%-56.3%$50.58MN/A-2.09N/ASNTISenti Biosciences1.75 of 5 stars$1.87-3.1%$8.50+354.5%-18.4%$50.34M$2.56M-0.174VTVTvTv Therapeutics2.3058 of 5 stars$15.49-9.0%$35.50+129.2%-1.3%$49.64M$1.02M-5.159Upcoming EarningsGap Down Related Companies and Tools Related Companies PRLD Competitors KALA Competitors CGTX Competitors NRXP Competitors KLRS Competitors ABVC Competitors GANX Competitors OSTX Competitors SNTI Competitors VTVT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHIO) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PHIO Stock Alerts